Congo Ebola cases pass 9,000 as outbreak reaches 65 health zones

The official count has passed 9,000 confirmed cases

Congo’s National Public Health Institute reported 9,066 confirmed Bundibugyo Ebola cases and 4,381 deaths in its October 13 situation report, according to Reuters. The Associated Press reported the same cumulative totals and said the latest report added 88 cases. These figures share the same government source and reporting cutoff, so their agreement is corroboration of what authorities published, not an independent audit of the line list. [1][2]

AP reported that 65 health zones across seven provinces had recorded cases and that officials believe confirmed infections represent only about one-third of the true total. That estimate is an attributed assessment, not a measured count. It also reported that many recorded deaths occurred outside treatment centers, a pattern that can delay isolation, testing and contact tracing. [2]

Reuters described the epidemic as Congo’s largest and deadliest recorded Ebola outbreak and the second largest globally after the 2014–2016 West Africa epidemic. WHO’s outbreak page confirms that Bundibugyo virus disease has no licensed vaccine or approved strain-specific treatment and says the response depends on early detection, infection prevention, contact tracing, safe burials, supportive care and community engagement. Those facts do not mean investigational vaccines or medicines have failed; trials discussed below have not yet established efficacy. [1][3]

U.S. travel policy is drawing scrutiny over response staffing

Reuters reported October 6 that the United States barred people with suspected or confirmed Ebola infection from being medically evacuated to the United States and established a 50-bed quarantine facility on a Kenyan air base for exposed U.S. citizens. It also reported a July do-not-board order for U.S.-bound travel by citizens who had been anywhere in Congo during the previous 21 days. The policy is documented; its precise effect on the epidemic is not settled. [5]

Samaritan's Purse president Franklin Graham told Reuters that Americans had previously made up about 80 percent of the organization's deployed Ebola staff but now accounted for roughly 20 percent, while deployment costs had more than doubled. Reuters also reported that one treatment center fell from six American doctors to one. Those figures describe one major responder's staffing and costs, not the entire national or international workforce. [5]

The U.S. Department of Health and Human Services said that framing overlooked a substantial federal response, including more than 120 CDC personnel in Congo and Uganda; the State Department said the United States had allocated about $780 million. WHO told Reuters it could not quantify the policy's overall impact without more evidence, while warning that measures deterring responders, funding withdrawals and disrupted supplies can slow outbreak control. These are competing assessments, not proof that one policy alone drove the outbreak's growth. [5][6][7]

The reported death toll has passed 4,000

The U.S. Centers for Disease Control and Prevention listed 8,442 confirmed cases and 4,080 deaths in Congo as of October 2. Earlier Congo government data reported by Reuters and Actualite.cd listed 8,300 cases and 4,018 deaths, alongside 2,162 recoveries, 842 people isolated or hospitalized and an 80.6 percent contact-follow-up rate. The totals likely reflect different reporting cutoffs or consolidation and should not be combined; all remain subject to retrospective revision. [6][9][11]

The national total can obscure sharply different local conditions. Radio Okapi reported 24 deaths among 50 positive cases recorded in Mahagi territory in Ituri, but no new local case there for nearly two months. Health officials said patients arriving from other hotspots and travel on routes that bypass checkpoints continue to complicate surveillance. The Mahagi figures are a territorial subset and should not be added to the national total. [12][14]

A trial is testing prevention after high-risk exposure

More than 250 people had enrolled in a randomized trial of the antiviral obeldesivir at the Rwampara treatment center in Ituri, the Associated Press reported October 3. The study began in July and aims to enroll about 1,000 people with high-risk exposure, including health workers and relatives of infected patients. It is testing whether a short course can prevent illness after exposure; it is not an approved cure, and enrollment does not establish that the drug works. [8][10]

A separate World Health Organization-sponsored PARTNERS trial is evaluating MBP134 and remdesivir in patients who already have confirmed Bundibugyo virus disease. That treatment study and the obeldesivir post-exposure study answer different questions and should not be presented as one trial. There is no approved vaccine or treatment specifically proven for this Bundibugyo outbreak; use of the Ervebo vaccine for response workers does not resolve uncertainty about cross-protection against this strain. [13][8][10]

Access, trust and basic logistics shape the response

WHO's French-language field report said 680 community health relays had been deployed in 17 health zones by September 17, with a target of 1,603 by the end of October. It reported that contact monitoring rose from below 15 percent early in the outbreak to above 85 percent and that about 2,000 alerts were being received each day, but it also identified inaccessible areas, staff shortages and community reluctance as continuing barriers. [14]

Radio Okapi described fuel shortages affecting response vehicles and an ambulance in Mahagi. Those practical constraints determine whether exposed families can be reached, sick people transported and contacts followed. The trial milestone is therefore one part of a larger public-health response whose success depends on safe access, trusted local communication, protective equipment, paid staff, transport and reliable care as well as an effective medicine. [12][14][8]

How the sources compare